[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362941-105":59,"doc-detail-362941-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","repurposing-acetyldigitoxin-as-a-potential-ezh2-inhibitor-for-non-small-cell-lung-cancer-a-computational-and-experimental-approach","Repurposing acetyldigitoxin as a potential EZH2 inhibitor for non-small cell lung cancer - a computational and experimental approach","","Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. The epigenetic regulator EZH2 is a promising therapeutic target due to its role in tumor progression and therapy resistance. This study integrates computational and experimental methods to repurpose FDA-approved drugs as EZH2 inhibitors. Virtual screening and molecular dynamics simulations identify acetyldigitoxin (ADT) as a potent EZH2 inhibitor with stronger binding and stable complexes than the known inhibitor GSK126, supported by favorable binding free energy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repurposing-acetyldigitoxin-as-a-potential-ezh2-inhibitor-for-non-small-cell-lung-cancer-a-computational-and-experimental-approach/362941/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repurposing-acetyldigitoxin-as-a-potential-ezh2-inhibitor-for-non-small-cell-lung-cancer-a-computational-and-experimental-approach/362941.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is EZH2 considered a therapeutic target in NSCLC?","Question",{"text":112,"@type":113},"EZH2 drives tumor progression and therapy resistance by regulating epigenetic gene silencing through H3K27me3. Its dysregulation is linked to poor clinical outcomes in NSCLC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was acetyldigitoxin (ADT) identified as an EZH2 inhibitor?",{"text":117,"@type":113},"The study used virtual screening and molecular dynamics simulations to evaluate candidate FDA-approved drugs. ADT showed superior binding affinity and complex stability compared with the known inhibitor GSK126.",{"name":119,"@type":110,"acceptedAnswer":120},"What biological effects did ADT show in vitro?",{"text":121,"@type":113},"ADT induced selective cytotoxicity against NSCLC A549 cells, reduced EZH2 expression, inhibited EZH2 histone methyltransferase activity, and decreased global H3K27me3 levels. It also caused G0/G1 cell cycle arrest and promoted apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362941,1790208716,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Repurposing acetyldigitoxin as a potential EZH2 inhibitor for nonsmall cell lung cancer: a computational and experimental approach  \nXiang Ji1 · Xiyan Wang1 · Ting Xiu2 · Min Gao1 · Degan Lu1  \nReceived: 25 April 2025 / Accepted: 6 February 2026 © The Author(s) 2026  \nAbstract  \nNon-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. The epigenetic regulator EZH2 is a promising therapeutic target due to its role in tumor progression and therapy resistance. This study combined computational and experimental methods to repurpose FDA-approved drugs as EZH2 inhibitors. Virtual screening and molecular dynamics simulations identified acetyldigitoxin (ADT) as a potent EZH2 inhibitor, demonstrating superior binding affinity (−10.90 kcal/mol) and complex stability compared to the known inhibitor GSK126 . ADT formed robust hydrogen bonds and hydrophobic interactions with key residues in the EZH2 binding site, supported by favorable binding free energy calculations (ΔGbinding = −34.73 kcal/mol) . In vitro, ADT exhibited selective cytotoxicity against NSCLCA549 cells (IC₅₀ = 32.4 nM) versus normal bronchial epithelial cells (IC₅₀ = 190 nM) . Treatment with ADT significantly reduced EZH2 expression and potently inhibited its histone methyltransferase activity, as directly evidenced by decreased global H3K27me3 levels. ADT induced G0/G1 cell cycle arrest and promoted apoptosis, accompanied by upregulation of pro-apoptotic genes (Bax, Caspase-3) and downregulation of anti-apoptotic (Bcl-2) and cell cycle (CyclinD1) genes. Our integrated findings position ADT as a repurposed drug candidate for targeting EZH2 in NSCLC, warranting further preclinical investigation including direct enzyme inhibition assays.  \n\n| Xiang Ji and Xiyan Wang have equally contributed as first author. |\n| --- |\n| Degan Lu is the primary corresponding author. |\n\n􀀍 Min Gao [flyingdreamss@163.com](flyingdreamss@163.com)  \n􀀍 Degan Lu[deganlu@126.com](deganlu@126.com)  \n1 Respiratory Department, First Affiliated Hospital of Shandong First Medical University, No. 16766, Jingshi Road, Qianfoshan Street, Lixia District, Jinan City 250014, Shandong Province, China  \n2 Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China  \n1 3  \nGraphical abstract  \nKeywords Non-small cell lung cancer · Enhancer of zeste homolog 2 · Acetyldigitoxin · Cardiac glycoside · Molecular dynamics · Cell cycle arrest · Apoptosis  \nIntroduction  \nNon-small cell lung cancer (NSCLC) remains one of the most prevalent and deadly malignancies worldwide, accounting for approximately 85% of all lung cancer cases [1, 2] . Despite advances in targeted therapies and immunotherapies, the prognosis for NSCLC patients varies significantly depending on the stage at diagnosis. According to recent data, the 5 year survival rate is 65% for localized disease, 37% for regional spread, and only 9% for distant metastasis, with an overall 5-year survival rate of 28% across all stages [3] . These stark statistics highlight the urgent need for novel therapeutic strategies that can effec  \ntively target the molecular drivers of NSCLC progression.  \nIn recent years, innovative approaches such as therapeutic protein-based vaccines have emerged as promising immunotherapeutic avenues. These vaccines are designed to elicit targeted immune responses against tumor-associated antigens, offering a potential strategy for personalized cancer therapy. However, their clinical application in NSCLC remains challenging due to issues related to antigen selection, immune evasion, and vaccine delivery [4] . Alongside immunotherapies, computational drug discovery has transformed oncology by enabling the rapid identification and optimization of novel inhibitors. Advanced in silico strategies, particularly those employing multi-sampling  \nalgorithms and multi-simulation validation, have proven critical for uncovering multit","cbCair8R4X5vQNAc","https://ap.wps.com/l/cbCair8R4X5vQNAc","pdf",2168963,18,"English","# Abstract\n## Computational identification\n## In vitro validation\n## Mechanistic findings\n## Significance and next steps","[{\"question\":\"Why is EZH2 considered a therapeutic target in NSCLC?\",\"answer\":\"EZH2 drives tumor progression and therapy resistance by regulating epigenetic gene silencing through H3K27me3. Its dysregulation is linked to poor clinical outcomes in NSCLC.\"},{\"question\":\"How was acetyldigitoxin (ADT) identified as an EZH2 inhibitor?\",\"answer\":\"The study used virtual screening and molecular dynamics simulations to evaluate candidate FDA-approved drugs. ADT showed superior binding affinity and complex stability compared with the known inhibitor GSK126.\"},{\"question\":\"What biological effects did ADT show in vitro?\",\"answer\":\"ADT induced selective cytotoxicity against NSCLC A549 cells, reduced EZH2 expression, inhibited EZH2 histone methyltransferase activity, and decreased global H3K27me3 levels. It also caused G0/G1 cell cycle arrest and promoted apoptosis.\"}]","Repurposing acetyldigitoxin as a potential EZH2 inhibitor for non-small cell lung cancer - a computational and experimental approach | PDF",1790149482,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be0bd29a9327ae89868d0616c3f38fcb.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/467c5c9b9c7a06c3fe828b5c7671ad32.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62f51d137b1571c9381d39bb4e9d5886.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faf4ec0d231117d011421610760af7ed.webp",980,1301]